title: A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.
abstract: A recent Elsevier survey of 200 urologists and oncologists who treat patients with castration-resistant prostate cancer (CRPC) identified a lack of physician confidence in understanding and using current clinical practices regarding the identification, treatment, and management of patients with CRPC. In response to this knowledge gap, a urologic oncology physician roundtable discussion was convened and a companion summary article created to provide a knowledge-based perspective for optimizing the identification, monitoring, and treatment of patients with metastatic CRPC (http://prostatecancer.urologiconcology.org/). Leading urology experts were selected to discuss how CRPC is defined and monitored, and to elaborate (through the presentation of 2 different cases) on considerations of how the currently approved chemotherapeutics, immunotherapy, and oral androgen inhibition agents can be used in the treatment of metastatic CRPC.
authors.affiliation: Carolina Urologic Research Center, Myrtle Beach, SC. nshore@gsuro.com.
authors.forename: Neal D
authors.initials: ND
authors.lastname: Shore
authors.forename: Raoul
authors.initials: R
authors.lastname: Concepcion
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Barocas
mesh_terms: D000737:Androstenols / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003657:Decision Making; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000737:Androstenols; D000970:Antineoplastic Agents; D019496:Cancer Vaccines